A new weight loss drug could see patients lose double the amount ... Wegovy and Mounjaro in the last three months of 2022, with companies racing to expand supply to meet the demand.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...

Wednesday, November 30, 2022. Graham has battled excess weight for years, cycling through trendy diets, various drugs, and even bariatric surgery. she started a new medication, Mounjaro ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more ... In the race to find Ozempic 2.0, a few stand-outs ...

Editor's Note: The following is part of a class project originally initiated in the classroom of Ball State University ...

Others quit because they achieved their weight loss goals — though it’s common to regain weight when you cease taking the drugs. The study authors plan to start clinical trials within the next ...

GLP-1 medications are breakthroughs for weight loss, diabetes ... a few stand-outs are emerging. While GLP-1 drugs have paved the way for a new era of healthcare, they have some drawbacks.

The U.S. Food and Drug Administration has added a new warning to drugs including ... can be prescribed for diabetes treatment or for weight loss management — have a few effects on the body.

Opens in a new tab or window ... agonists for weight loss has grown, so too has their use in children. Currently, liraglutide and semaglutide are the only two GLP-1 drugs FDA-approved to treat ...